1291 results found
This section provides frequently asked questions about the Good institutional practice guide (the Guide).
The Investigator Grants Peer Review Mentor (PRM) video features senior researchers discussing their approach to organising, assessing, scoring and comparing Investigator and other NHMRC grant applications equitably. This video resource is to support peer reviewers of NHMRC grants.
Professor Greg Fox is a respiratory doctor and clinical trialist at the University of Sydney and Director of the Sydney Vietnam Institute who is contributing to the momentum towards tuberculosis (TB) elimination. Professor Fox received the 2021 NHMRC David Cooper Clinical Trials and Cohort Studies Award, recognising the highest ranked recipient in the Clinical Trials and Cohort Studies scheme.
The National Health and Medical Research Council (NHMRC) is dedicated to the adoption and responsible use of Artificial Intelligence (AI). This Transparency Statement outlines our approach to AI use within the NHMRC, in accordance with the DTA's policy for responsible AI in government.
Frontline care for people experiencing mental health conditions is usually provided by general practitioners (GPs). These conditions – whose total cost to society has been estimated at $10.9 billion per year1 – impact on a person’s physical, social and financial wellbeing, work productivity and more, and when work-related they are particularly complex and challenging to manage.
NHMRC sought a review of legal and policy barriers in Australia to promote a competitive and accessible clinical trials sector. This review details current indemnity and insurance arrangements concerning clinical trials across the public and private sectors.
Five expert research teams will share in an investment of $7 million in funding to support targeted health and medical research into the commercial determinants of Aboriginal and Torres Strait Islander health.
NHMRC has revised its MREA progress report template to gather more information to support evaluation of achievements against identified aims and collect data on clinical trials registration information that will contribute to NHMRC’s policy and evaluation processes.
‘Melanoma is the most common cancer for 15-39 year old Australians—with the highest ‘years of life lost’ of any cancer’1
The following is a summary of the CEO Statement. For detailed information, please check the CEO Statement tab.